Investment Rating - The report does not explicitly state an investment rating for the pharmaceutical industry [2]. Core Insights - During the period from March 9 to March 15, 2026, a total of 98 innovative drugs/improved new drugs were submitted for clinical trials or market approval, with 82 domestic and 16 imported applications [8]. - A total of 86 innovative drugs/improved new drugs received "implied permission" for clinical trials, including 48 chemical drugs and 37 biological drugs [8]. - Notable drugs include SG-12 injection for chronic hepatitis B and SKB-575 injection for atopic dermatitis, both of which received clinical trial approval [9][10]. Summary by Sections 1. Domestic Innovative Drugs/Improved New Drugs - 1.1 Overview: 98 applications for clinical trials or market approval were recorded, with 82 domestic and 16 imported [8]. - 1.2 Clinical Trial Approvals: 86 drugs received implied permission for clinical trials, including significant drugs like SG-12 and SKB-575 [8][9]. - 1.3 Market Approvals: No new drugs were approved for market this week [29]. 2. Domestic Generic Drugs/Biosimilars - 2.1 Overview: 41 applications for generic drugs were submitted, with 36 for new registration and 4 for clinical trials [30]. - 2.2 Consistency Evaluation: 6 products passed consistency evaluation, with a total of 55 products deemed equivalent [31]. 3. Policy and Regulation - 3.1 Policy Overview: The report summarizes key policies affecting the pharmaceutical industry, including the implementation of the Drug Administration Law [3]. - 3.2 Detailed Policy Explanation: Specific regulations and their implications for the industry are discussed [3]. 4. Global Innovative Drug Development - 4.1 Global R&D Overview: The report highlights the progress of the top 10 innovative drugs globally, including significant approvals and clinical trial results [4]. - 4.2 Clinical Trial Outcomes: The report details both successful and failed clinical trials for various drugs, indicating the competitive landscape [4].

Investment Rating - The report does not explicitly state an investment rating for the industry, but it highlights significant developments that may influence future ratings [2]. Core Insights - The invasive brain-machine interface (BMI) has received regulatory approval, marking a milestone in the domestic industry and indicating a shift from conceptual research to clinical application. This technology is expected to enhance the quality of life for patients with cervical spinal cord injuries [2][10]. - The report emphasizes the importance of focusing on specialized medical service providers with core neurosurgical clinical resources and data access, as well as innovative medical device companies with invasive BMI technology platforms [2]. Market Weekly Review - The pharmaceutical and biotechnology sector experienced a slight decline of 0.22% from March 9 to March 13, underperforming the CSI 300 index, which rose by 0.19%. Notable performers included medical consumables (up 4.1%), active pharmaceutical ingredients (up 1.32%), and vaccines (up 1.29%), while medical devices (down 2.04%), medical research outsourcing (down 1.63%), and chemical preparations (down 0.82%) lagged behind [7][8]. - Individual stock performances showed significant gains for Jiuan Medical (up 20.1%), Baolait (up 17.8%), and Haitai Biological (up 17%), while Huakang Medical (down 6.9%), ST Weiming (down 6.8%), and Yirui Technology (down 6.7%) faced notable declines [10]. Industry News and Key Company Announcements Important Industry Events - On March 13, the National Medical Products Administration approved the innovative product registration application for the implanted brain-machine interface hand function compensation system by Boruikang Medical, marking the global first for invasive BMI medical devices entering clinical application [10][11]. Industry News - Eli Lilly announced plans to invest $3 billion over the next decade to expand its supply chain capacity in China, focusing on local production and supply systems for oral solid formulations, including the GLP-1 receptor agonist orforglipron [11]. - GlaxoSmithKline (GSK) and Alfasigma entered a licensing agreement for the development and commercialization of linerixibat, a trial drug for primary biliary cholangitis, with GSK receiving an upfront payment of $300 million [12]. Company Announcements - Junshi Biosciences reported a total revenue of 2.498 billion yuan for 2025, a year-on-year increase of 28.23%, but also a net loss of 875 million yuan [11]. - Xizang Pharmaceutical announced a total revenue of 2.982 billion yuan for 2025, a year-on-year increase of 6.23%, with a proposed cash dividend of 563 million yuan [11]. - Aide Pharmaceutical projected a total revenue of 1.197 billion yuan for 2025, reflecting an 8% year-on-year growth, driven by operational efficiency improvements and product approvals [11].

Investment Rating - The report does not explicitly state an investment rating for the industry, but it highlights significant developments that may influence future ratings [2]. Core Insights - The invasive brain-computer interface (BCI) has received regulatory approval, marking a milestone in the domestic BCI industry, transitioning from concept development to clinical application. This product is designed for patients with quadriplegia due to cervical spinal cord injuries and utilizes minimally invasive implantation and wireless communication technology [2][10]. - The report suggests focusing on specialized medical service providers with core neurosurgical clinical resources and data access, as well as innovative medical device companies with invasive BCI technology platforms [2]. Market Weekly Review - The pharmaceutical and biotechnology sector experienced a slight decline of 0.22% from March 9 to March 13, underperforming the CSI 300 index, which rose by 0.19%. Notable performers included medical consumables (up 4.1%), raw materials (up 1.32%), and vaccines (up 1.29%), while medical devices (down 2.04%), medical research outsourcing (down 1.63%), and chemical preparations (down 0.82%) lagged behind [7][8]. - Individual stock performances showed significant gains for Jiuan Medical (up 20.1%), Baolait (up 17.8%), and Haitai Biological (up 17%), while Huakang Medical (down 6.9%), ST Weiming (down 6.8%), and Yirui Technology (down 6.7%) faced notable declines [10]. Industry News and Key Company Announcements Important Industry Events - On March 13, the National Medical Products Administration approved the innovative product registration application for the implanted brain-computer interface hand function compensation system by Boruikang Medical, marking the global first for invasive BCI medical devices entering clinical application [10]. Industry News - Eli Lilly announced plans to invest $3 billion over the next decade to expand its supply chain capacity in China, focusing on local production and supply systems for oral solid formulations, including the GLP-1 receptor agonist orforglipron [11]. - GlaxoSmithKline (GSK) and Alfasigma entered a licensing agreement for the development and commercialization of linerixibat, a trial drug for primary biliary cholangitis, with GSK receiving an upfront payment of $300 million [12]. Company Announcements - Junshi Biosciences reported a total revenue of 2.498 billion yuan for 2025, a year-on-year increase of 28.23%, but a net loss of 875 million yuan [11]. - Tibet Pharmaceutical achieved a total revenue of 2.982 billion yuan for 2025, a year-on-year increase of 6.23%, with a proposed cash dividend of 563 million yuan [11]. - Aide Pharmaceutical projected a total revenue of 1.197 billion yuan for 2025, reflecting an 8% year-on-year growth, driven by operational efficiency improvements and product approvals [11].

Core Viewpoint - The leading companies in the growth hormone sector, Changchun High-tech and Anke Bio, are facing declining revenues and are seeking new growth avenues through diversification into other therapeutic areas [1][2][3]. Group 1: Company Performance - Both Changchun High-tech and Anke Bio reported a decline in revenue and net profit for 2024, with Changchun High-tech experiencing its first annual revenue drop in nearly 20 years, showing a 5.66% decrease in revenue and a 44.95% drop in net profit for Q1 2025 [2][3]. - Anke Bio's revenue and net profit also fell by over 10% in the previous year, with a 4% decline in both metrics for Q1 2025 [2][3]. Group 2: Market Dynamics - The growth hormone market in China has expanded significantly, from $600 million in 2018 to $1.7 billion in 2022, capturing 34% of the global market share, surpassing the United States [2]. - The introduction of price-cutting measures in 2022 has pressured the revenues of the two leading companies, leading to a contraction in their growth hormone business [2][3]. Group 3: Product Development and Diversification - Changchun High-tech and Anke Bio are both attempting to diversify their product lines beyond growth hormones, with Changchun High-tech planning to expand into pediatrics, women's health, and anti-aging sectors [4][5]. - Changchun High-tech's subsidiary, GenSci, has seen over 76% of its revenue coming from growth hormones, while Anke Bio's growth hormone sales account for nearly 70% of its total revenue [3]. - Both companies have initiated clinical trials for new products, with Changchun High-tech focusing on innovative drugs and Anke Bio expanding into antiviral and oncology treatments [5].

Core Viewpoint - The company has received FDA approval for clinical trials of GenSci128 tablets, a targeted therapy for patients with TP53 Y220C mutation in advanced or metastatic solid tumors [1][2]. Group 1: Drug Information - Product Name: GenSci128 tablets - Application: Clinical trial approval in the US - Acceptance Number: IND 174059 - Applicant: Changchun JinSai Pharmaceutical Co., Ltd. - Approval Conclusion: Permission granted for clinical trials in the US - Indication: Local advanced or metastatic solid tumors with TP53 Y220C mutation [1]. Group 2: Drug Mechanism and Development - GenSci128 is a class 1 new chemical drug designed as a selective reactivator for TP53 Y220C mutation, aiming to restore the normal conformation and function of the mutated protein [2]. - Preclinical data indicates that GenSci128 has good efficacy and safety [2]. - The drug has also been approved for clinical trials in China for the same indication [2]. Group 3: Company Impact - Successful progress in clinical trials could help the company expand its business structure, optimize product offerings, and enhance core competitiveness [3]. - The company will actively promote the research and development of this project and comply with disclosure obligations regarding project progress [4].

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Jinsai Pharmaceutical, received approval from the US FDA to conduct clinical trials for GenSci128 tablets, a selective reactivator targeting the TP53 Y220C mutation for treating locally advanced or metastatic solid tumors carrying this mutation [1] Group 1 - GenSci128 tablets have already been approved for clinical trials in China [1] - Successful progress in the clinical trial application will help the company broaden its business structure and optimize its product portfolio [1] - The development of GenSci128 is expected to enrich and enhance the strategic product line layout, thereby improving the company's core competitiveness [1]

Group 1: Company Performance - Western Gold achieved operating revenue of 7.001 billion yuan in 2024, a year-on-year increase of 56.68%, and net profit of 290 million yuan, turning from loss to profit [1] - Jihong Co. reported operating revenue of 5.529 billion yuan in 2024, a year-on-year decrease of 17.41%, with net profit down 47.28% to 182 million yuan [2] - Sanli Co. achieved operating revenue of 227 million yuan in 2024, a year-on-year increase of 14.35%, but reported a net loss of 49.88 million yuan, narrowing the loss by 56.50% [2] - Sanli Co. reported operating revenue of 2.590 billion yuan in 2024, a year-on-year increase of 25.25%, with net profit of 68.09 million yuan, up 59.07% [4] - Huaiqi Mountain achieved operating revenue of 1.631 billion yuan in 2024, a year-on-year increase of 15.60%, with net profit of 196 million yuan, up 17.74% [6] - Huayuan Holdings reported operating revenue of 2.449 billion yuan in 2024, a year-on-year increase of 1.60%, with net profit of 70.74 million yuan, up 739% [8] - Hangfa Power achieved operating revenue of 47.880 billion yuan in 2024, a year-on-year increase of 9.48%, but net profit decreased by 39.48% to 860 million yuan [10] - Zhongcai Energy reported operating revenue of 2.324 billion yuan in 2024, a year-on-year decrease of 24.21%, with net profit down 94.70% to 760,240 yuan [10] - Longxing Technology achieved operating revenue of 4.355 billion yuan in 2024, a year-on-year increase of 1.95%, with net profit of 142 million yuan, up 28.70% [11] - Jinying Co. reported operating revenue of 1.308 billion yuan in 2024, a year-on-year decrease of 4.52%, with net profit down 36.73% to 22.35 million yuan [12] - Zhujiang Co. achieved operating revenue of 1.558 billion yuan in 2024, a year-on-year decrease of 52.38%, but net profit turned to profit at 15.57 million yuan [12] - Chuanwang Media reported operating revenue of 288 million yuan in 2024, a year-on-year increase of 20.05%, but net profit decreased by 24.02% to 23.80 million yuan [13] - Ronglian Technology achieved operating revenue of 2.022 billion yuan in 2024, a year-on-year decrease of 14.91%, with net profit of 28.11 million yuan, up 107.87% [13] - Oufeiguang reported operating revenue of 20.437 billion yuan in 2024, a year-on-year increase of 21.19%, but net profit decreased by 24.09% to 58.38 million yuan [14] Group 2: Dividend Proposals - Western Gold proposed a cash dividend of 0.5 yuan per 10 shares [1] - Jihong Co. proposed a cash dividend of 1.58 yuan per 10 shares [2] - Sanli Co. proposed a cash dividend of 1.50 yuan per 10 shares [4] - Huaiqi Mountain proposed a cash dividend of 4.00 yuan per 10 shares [6] - Huayuan Holdings proposed a cash dividend of 1.00 yuan per 10 shares [8] - Hangfa Power proposed a cash dividend of 0.97 yuan per 10 shares [10] - Zhongcai Energy proposed a cash dividend of 0.05 yuan per 10 shares [10] - Longxing Technology proposed a cash dividend of 1.20 yuan per 10 shares [11] - Jinying Co. proposed a cash dividend of 1.00 yuan per 10 shares [12] - Zhujiang Co. proposed a cash dividend of 1.25 yuan per 10 shares [12] - Chuanwang Media proposed a cash dividend of 1.25 yuan per 10 shares [13] - Ronglian Technology proposed a cash dividend of 0.0425 yuan per share [13] - Oufeiguang proposed a cash dividend of 0.0178 yuan per share [14]